AI Science Tracker

Cleveland Clinic

2 discoveries from 2020 to 2024

Discoveries

deepDTnet repurposes topotecan as an RORγt inhibitor for multiple-sclerosis models

The deep-learning network deepDTnet predicted retinoic-acid-receptor-related orphan receptor gamma-t (RORγt) as a previously unrecognized target of topotecan. Biochemical assays showed direct inhibition (IC50 0.43 μM), and topotecan improved outcomes in a mouse experimental autoimmune encephalomyelitis model of multiple sclerosis.

Technology: deepDTnet, heterogeneous drug–gene–disease network embedding with deep learning

Publication: Peer-reviewed paper · Test context: direct test. Catalog categories, not an evidence grade.

Result, AI contribution and limits

Evidence context (descriptions follow the cited sources; test type is a catalog classification):

  • Publication status: Peer-reviewed paper
  • Test type: direct test
  • Tested: Biochemical assays showed direct inhibition (IC50 0.43 μM), and topotecan improved outcomes in a mouse experimental autoimmune encephalomyelitis model of multiple sclerosis.
  • Still unknown: Evidence is preclinical: direct target and mouse-model assays do not establish safety or effectiveness in people with multiple sclerosis. Topotecan is an established anticancer drug, and its new target/indication remains a repurposing hypothesis.
  • AI role: The model integrated 15 types of chemical, genomic, phenotypic and cellular network profiles to rank new drug targets. It nominated RORγt for topotecan, which the team tested using direct binding/transcriptional assays and a mouse EAE disease model.

Evidence sources: https://pubmed.ncbi.nlm.nih.gov/34123272/

Source checked · editorial details

The source page was checked against this entry. Independent confirmation is not assessed by this label.

Source type: paper. Paper: linked separately.

Review scope and date are not recorded; source checked does not establish full-text review.

Citations: in the top 1% of works of the same type, year and subfield (OpenAlex work metrics, 366 citations; as of 15 Nov 2026). Attention, not a measure of correctness; not part of the score.

Editorial assessment: Impact 3/5 · Validation 3/5 · Novelty 3/5. Impact and novelty are editorial judgments; validation follows the annotated test type where one exists. Not an evidence grade. Scoring criteria.

Follow-up and relationships

No follow-up recorded; this is not a claim that no follow-up exists.

Follow-up review scope and date are not recorded.

No source-supported relationships recorded.

Open the interactive profile for the timeline, or browse all organizations and model families.